HUAWEI
5.1.2023 05:30:43 CET | Business Wire | Press release
Huawei has released a white paper on the Top 10 Site Power Trends at an event. According to Yao Quan, President of Huawei Site Power Facility Domain, 2022 was a challenging year for carriers due to the global energy crisis and the increase in oil and electricity prices. Against this backdrop, Huawei shares the top ten site power trends to help carriers reduce energy consumption and achieve carbon neutrality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104006005/en/
Yao Quan, President of Huawei Site Power Facility Domain (Photo: Business Wire)
Trend 1: Energy Digitalization
With the global consensus on achieving carbon neutrality, the ICT sector has been striving to go green (Green ICT) and helping other sectors to do the same (ICT for Green). Huawei integrates digital technologies and power electronics technologies and lets bits manage watts, promoting the low-carbon transformation of the ICT and other sectors.
Trend 2: Low-Carbon Network
To achieve carbon neutrality, carriers seek to build a green and low-carbon network throughout the lifecycle, from network construction and power supply to operation.
Site structure is simplified by changing from equipment rooms and cabinets to poles. PV systems are installed on sites to reduce grid power consumption. Digitalization of sites helps perform intelligent O&M, reducing manual site visits. Sites with abnormal energy consumption and carbon emissions can be pinpointed in real-time, further reducing site O&M costs and carbon emissions.
Trend 3: Green Power Utilization
As new energy technologies develop and new business models emerge, site power supply becomes diversified, and clean energy sources such as solar, wind, and hydrogen are utilized more. With the decreasing costs for clean energy, carriers will increase the proportion of self-built green power plants besides PPA.
Trend 4: Site Simplification
Conventional sites are often deployed in equipment rooms or cabinets, in which air conditioners consume a large amount of energy, causing low efficiency and high electricity fees. To address this, the trend is to simplify site structure by changing from rooms to cabinets and poles, reducing energy consumption and carbon emissions.
Trend 5: High Efficiency
Efficiency optimization is no longer confined to components. The focus changes from rectifiers to the link of generation, conversion, storage, distribution, and consumption. By deploying sites in cabinets or on poles, the SEE (Site Energy Efficiency) can be raised to 97%, and site footprint is also reduced. Additionally, energy devices and wireless devices are coordinated to implement precise energy efficiency management and energy consumption optimization.
Trend 6: Smart Sites
Conventional sites usually adopt dumb components that do not support refined management. Energy consumption and carbon emission of sites cannot be viewed, and energy saving and carbon reduction cannot be performed. Besides, site maintenance relies heavily on manual site visits, leading to high O&M costs. Smart site management and automatic O&M can address these issues by providing real-time energy efficiency and carbon emission data and improving site operation efficiency.
Trend 7: Telecom Sites to Shared Sites
Telecom sites have the potential to become shared sites, supplying power to the public and transforming telecom carriers into integrated service providers. Site service modes will become more diversified, offering new services such as virtual power plant (VPP), electricity access with the network, and rent offset with electricity to increase site revenues and unlock the value of telecom sites.
Trend 8: Multi-Mode Architecture
As more types of power sources are used, site power must be able to support different input modes. Shared sites also need to meet power supply requirements of different loads, requiring multi-mode output. Thus, the multi-mode architecture will become mainstream.
Trend 9: Power Backup + Energy Storage
In traditional telecom sites, energy storage only provides backup power for communications equipment. Now carriers start to develop new business models such as peak staggering and VPP. Energy storage participates in power grid scheduling. Site batteries develop from backup power to an integrated energy storage system.
Trend 10: Security and Reliability
For sites, security and reliability lie in network security and hardware safety. As energy digitalization gains momentum, governments and industries are working to prevent attacks and security risks. A series of security and safety specifications are released.
Download the White Paper: https://digitalpower.huawei.com/attachments/index/0164454533db4b01a02d144ae0eb209d.pdf
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104006005/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
